Providers received billions from drug and device companies

Share this content:
Providers Received Billions From Drug/Device Companies
Providers Received Billions From Drug/Device Companies

(HealthDay News) -- About 546,000 doctors and 1,360 teaching hospitals in the United States received billions of dollars from drug and medical device makers in the second half of 2013, according to data released Tuesday by the Centers for Medicare & Medicaid Services. The financial benefits ranged from research grants to trips, and totaled nearly $3.5 billion from August through December last year, the Associated Press reported.

The data -- which included the names of companies and many of the recipients -- was released under a new program called Open Payments, which was created under the new health care law. The goal is to reduce ethical conflicts in medicine by allowing patients to easily find information about their doctors online. In future, the information will cover the full 12 months of each year.

The data released Tuesday show that orthopedists, cardiologists, and adult medicine specialists were among the health care providers most likely to receive financial benefits from drug and medical device makers, the AP reported. Cash payments were the most common type of benefit, followed by in-kind gifts and services, and stock options. Some doctors also had part ownership of companies, and this was included in the data.

The companies at the top of the payout list included Genentech, Pfizer, and DePuy Synthes, the AP reported.

Health Highlights: Oct. 2, 2014
More Information

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs